AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) shares fell 4.6% during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $30.00 to $28.00. JPMorgan Chase & Co. currently has a neutral rating on the stock. AnaptysBio traded as low as $21.17 and last traded at $21.48. 79,543 shares were traded during mid-day trading, a decline of 73% from the average session volume of 297,461 shares. The stock had previously closed at $22.52.
ANAB has been the topic of several other reports. Stifel Nicolaus began coverage on AnaptysBio in a research report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 target price on the stock. BTIG Research initiated coverage on AnaptysBio in a report on Monday, February 26th. They issued a “buy” rating and a $55.00 target price on the stock. Piper Sandler assumed coverage on AnaptysBio in a report on Friday, February 16th. They issued an “overweight” rating and a $80.00 target price on the stock. Finally, Wedbush upgraded AnaptysBio from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $20.00 to $34.00 in a research report on Tuesday, March 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and an average price target of $44.71.
Insider Buying and Selling at AnaptysBio
In related news, CEO Daniel Faga sold 145,940 shares of the company’s stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the transaction, the chief executive officer now directly owns 752,087 shares in the company, valued at approximately $17,132,541.86. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Daniel Faga sold 145,940 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the transaction, the chief executive officer now owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric J. Loumeau sold 5,000 shares of AnaptysBio stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider now directly owns 3,240 shares of the company’s stock, valued at approximately $81,000. The disclosure for this sale can be found here. Insiders sold 168,605 shares of company stock valued at $3,839,195 in the last quarter. Company insiders own 35.50% of the company’s stock.
Institutional Investors Weigh In On AnaptysBio
Large investors have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new stake in AnaptysBio in the second quarter worth $34,000. Tower Research Capital LLC TRC grew its holdings in AnaptysBio by 248.8% in the third quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 2,565 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 2,390 shares during the period. BNP Paribas Arbitrage SA grew its holdings in AnaptysBio by 75.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 2,142 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of AnaptysBio by 134.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 3,381 shares during the last quarter.
AnaptysBio Price Performance
The stock has a market capitalization of $570.52 million, a price-to-earnings ratio of -3.42 and a beta of -0.30. The business’s fifty day moving average price is $23.95 and its 200-day moving average price is $20.25.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.